ClinicalTrials.gg
CompletedNCT02756611VENICE IUpdated Apr 10, 2023Results posted

A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)

A Phase 3 interventional study of Venetoclax in Chronic Lymphocytic Leukemia, sponsored by AbbVie. Completed at 67 sites in 21 countries. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2023-04-10.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
258
Allocation
Not applicable
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell — 21 open to participants now, 42 under way, 8 of them phase 3. venetoclax · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
9th of 69
258 · median 72
Started
2016
with 5 others
Phase 3
15 of 69
3 open now
Registered
13th of 69
by date
Lead sponsor
11 of 69
AbbVie

Among the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 9th largest by enrollment, is one of 6 that started in 2016, is one of 15 in phase 3, and was the 13th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

21 of the 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 12 countries. Recruiting first, the newest first:

16 more — sign in →

By country, each count listing its studies:

All 21 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing venetoclax in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of venetoclax monotherapy in participants with relapsed/refractory CLL with or without the 17p deletion or TP53 mutation, including those who have received prior treatment with a B-cell receptor inhibitor.

Read the detailed description

Following the Screening period, all eligible participants initiate venetoclax on a once daily (QD) dosing schedule. To mitigate the risk for tumor lysis syndrome (TLS), dosing will start with a 5-week dose titration phase.

Participants may receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator assessment), do not have unacceptable toxicity and do not meet any of the criteria for subject discontinuation. In countries where venetoclax is not commercially available, participants who continued to derive benefit after 2 years of treatment may extend their treatment for up to 2 additional years in an extended access phase. Participants in the extended access phase of this study who continue to derive benefit from venetoclax after the 2-year extension and are transferring to the venetoclax extension study, Study M19-388 (NCT03844048), may remain in Extended Access for up to 1 additional year or until the extension study is approved and initiated at the site, whichever is sooner.

03

Conditions studied

  • Chronic Lymphocytic Leukemia

Keywords

  • Oncology
  • Chronic Lymphocytic Leukemia
  • 17p Deletion
  • TP53 Mutation
  • Relapsed
  • Refractory
  • B-Cell receptor inhibitor
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant has (ECOG) performance score of less than or equal to 2
  • Participant has disease (received at least 1 prior therapy)
  • Participant has diagnosis of CLL that meets published 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute Working Group (IWCLL NCI-WG) Guidelines and:

    • has an indication for treatment according to the 2008 Modified IWCLL NCI-WG criteria
    • has clinically (lymphocytosis greater than 5 × 10\^9/L and/or palpable and measurable nodes by physical exam and/or organomegaly assessed by physical exam)
  • In addition, participants:

    • with or without 17p deletion or TP53 mutation, assessed by a local laboratory in bone marrow or peripheral blood are eligible
    • may have been previously treated with a prior B-cell receptor inhibitor
  • Participant must have adequate bone marrow function, coagulation profile, renal, and hepatic function, per laboratory at Screening

Exclusion criteria

Exclusion Criteria:

  • Participant has developed Richter's transformation or Prolymphocytic leukemia
  • Participant has previously received venetoclax
  • History of active other than CLL within the past 2 years prior to first dose of venetoclax, with the exception of:

    • adequately treated in situ carcinoma of the cervix uteri
    • adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin
    • previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
  • Participant has active and uncontrolled cytopenias (for 2 weeks prior to Screening), including autoimmune hemolytic anemia and idiopathic thrombocytopenic purpura despite low dose
  • Participant has undergone an stem cell transplant
  • Treatment with any of the following within five half-lives or 14 days (if half-life unknown) as applicable prior to the first dose of venetoclax, or adverse effect(s)/toxicity(s) of the previous therapy have not resolved to \< National Cancer Institute (NCI CTCAE) v4.03 Grade 2:

    • Any anti-cancer therapy including chemotherapy, or radiotherapy;
    • therapy, including targeted small molecule agents
  • Participant is (HIV) positive
  • Participant has known allergy to both xanthine oxidase inhibitors and rasburicase
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Venetoclax

    Venetoclax will be administered orally once daily (QD) beginning with a dose-titration phase. The initial venetoclax dose is 20 mg QD. After 1 week of treatment at 20 mg QD, the dose will be escalated to 50 mg QD followed by subsequent increases, each after 1 week, to 100 mg QD, 200 mg QD and the maximum dose of 400 mg QD. Participants may continue to receive venetoclax for up to 2 years provided they continue to tolerate the drug, have no evidence of disease progression (based on investigator's assessment), do not have unacceptable toxicity, and do not meet any of the criteria for discontinuation. In countries where venetoclax is not commercially available, participants who continue to derive benefit after 2 years of treatment may be able to extend their treatment for up to 2 additional years, plus one additional year until the venetoclax extension study was open, determined on a case by case basis.

    Drug: Venetoclax

Interventions

  • Tablets for oral administration

    Also known as: ABT-199, VENCLEXTA®

06

What researchers measure

Primary outcomes

  1. Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis

    Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (IWCLL NCI-WG) criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes. CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

Secondary outcomes

  1. Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Primary Analysis

    Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  2. Overall Response Rate (ORR) - Primary Analysis

    Overall response rate was defined as the percentage of participants with an overall best response of CR, CRi, nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 modified IWCLL NCI-WG criteria assessed by the investigator. CR and CRi are defined above. nPR is defined as for CR but bone marrow nodules could be identified histologically. For PR at least 2 of the following must be met: * 50% decrease in peripheral blood lymphocyte count from the Baseline value; * 50% reduction in lymphadenopathy; * 50% reduction in the size of the liver and/or spleen (if abnormal prior to therapy); In addition at least 1 of the following criteria must be met: * Neutrophils \> 1,500/μL or ≥ 50% improvement over Baseline; * Platelets \> 100,000/μL or ≥ 50% improvement over Baseline; * Hemoglobin \> 11.0 g/dL or ≥ 50% improvement over Baseline without transfusions or exogenous growth factors. PR must have been confirmed at least 7 weeks later.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  3. Duration of Overall Response (DOR) - Primary Analysis

    Duration of response was defined as the time from the date of first response (CR, CRi, nPR, or PR) to the earliest date that progressive disease (PD) was objectively documented (radiographic or clinical) or death. Duration of response was analyzed by Kaplan-Meier (K-M) methodology. If a participant was still responding the data were censored at the date of the last available disease assessment prior to the data cutoff date.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  4. Time to Progression (TTP) - Primary Analysis

    Time to progression was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical). Participants who did not experience disease progression were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline disease assessments were censored at the first dose date plus 1 day. Time to progression was estimated using Kaplan-Meier methodology.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  5. Progression-Free Survival (PFS) - Primary Analysis

    Progression-free survival (PFS) was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical) or death. Participants who did not experience disease progression or death were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline tumor assessment or clinical assessment for progression were censored at the date of first dose plus 1 day. Progression-free survival was analyzed by Kaplan-Meier methodology.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  6. Overall Survival (OS) - Primary Analysis

    Overall survival (time to death) was defined as the time from the first dose date of venetoclax to the date of death. If a participant had not died the data were censored at the date when they were last known to be alive prior to the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  7. Change From Baseline in Functional Assessment of Cancer Therapy - Leukemia Questionnaire (FACT-Leu)

    The FACT-Leu is a 44-item, leukemia-specific questionnaire designed to assess health-related quality of life (HRQoL) and leukemia-specific symptoms using a core set of questions (Functional Assessment of Cancer Therapy-General; FACT-G), and a cancer site-specific leukemia subscale. Questions are scored on a scale from 0 (not at all) to 4 (very much). FACT-G consists of 27 general items divided into 4 primary HRQoL domains: Physical Well-being (PWB; 7 items; score range 0-28), Social/Family Well-being (SWB; 7 items; score range 0-28), Emotional Well-being (EWB; 6 items; score range 0-24), Functional Well-being (FWB; 7 items; score range 0-28). The leukemia subscale consists of 17 items (score range 0-68) that assess patient concerns relating to leukemia. Three summary scales were calculated: FACT-Trial Outcome Index composed of the PWB, FWB, and leukemia subscale (score range 0-124); FACT-G (score range 0-108) and the FACT-Leu Total (range 0-176). Higher scores reflect better HRQoL.

    Time frame: Baseline and Weeks 48 and 108

  8. Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue)

    The FACIT-Fatigue questionnaire measures fatigue and its effect on functioning and daily activities. The FACIT-Fatigue includes 13 items answered on a 5-point rating scale based on a 7-day recall period. Scores range from 0 to 52, with lower scores reflecting greater fatigue.

    Time frame: Baseline and Weeks 48 and 108

  9. Change From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Health Index Score

    The EQ-5D-5L is a generic measure of health status consisting of two parts: a descriptive system consisting of 5 items and a visual analog scale (VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participant is asked to rate each dimension on 5 levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems). The scores for the 5 dimensions are used to compute a single health utility index score representing the general health status of the individual. The health index score ranges from zero (defined as a health state equivalent to being dead) to 1 (full health).

    Time frame: Baseline and Weeks 48 and 108

  10. Change From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Visual Analog Scale Score

    The EQ-5D-5L is a generic measure of health status consisting of two parts, a descriptive system consisting of 5 items and a visual analog scale (VAS). The VAS assesses the participant's self-rated overall health on a scale from 0 (worst health imaginable) to 100 (best health imaginable).

    Time frame: Baseline and Weeks 48 and 108

Other outcomes

  1. Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Final Analysis

    Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes. CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  2. Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Final Analysis

    Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  3. Overall Response Rate (ORR) - Final Analysis

    Overall response rate was defined as the percentage of participants with an overall best response of CR, CRi, nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 modified IWCLL NCI-WG criteria assessed by the investigator. CR and CRi are defined above. nPR is defined as for CR but bone marrow nodules could be identified histologically. For PR at least 2 of the following must be met: * 50% decrease in peripheral blood lymphocyte count from the Baseline value; * 50% reduction in lymphadenopathy; * 50% reduction in the size of the liver and/or spleen (if abnormal prior to therapy); In addition at least 1 of the following criteria must be met: * Neutrophils \> 1,500/μL or ≥ 50% improvement over Baseline; * Platelets \> 100,000/μL or ≥ 50% improvement over Baseline; * Hemoglobin \> 11.0 g/dL or ≥ 50% improvement over Baseline without transfusions or exogenous growth factors. PR must have been confirmed at least 7 weeks later.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  4. Duration of Overall Response (DOR) - Final Analysis

    Duration of response was defined as the time from the date of first response (CR, CRi, nPR, or PR) to the earliest date that progressive disease (PD) was objectively documented (radiographic or clinical) or death. Duration of response was analyzed by Kaplan-Meier (K-M) methodology. If a participant was still responding the data were censored at the date of the last available disease assessment prior to the data cutoff date.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  5. Time to Progression (TTP) - Final Analysis

    Time to progression was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical). Participants who did not experience disease progression were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline disease assessments were censored at the first dose date plus 1 day. Time to progression was estimated using Kaplan-Meier methodology.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  6. Progression-Free Survival (PFS) - Final Analysis

    Progression-free survival (PFS) was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical) or death. Participants who did not experience disease progression or death were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline tumor assessment or clinical assessment for progression were censored at the date of first dose plus 1 day. Progression-free survival was analyzed by Kaplan-Meier methodology.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  7. Overall Survival (OS) - Final Analysis

    Overall survival (time to death) was defined as the time from the first dose date of venetoclax to the date of death. If a participant had not died the data were censored at the date when they were last known to be alive prior to the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

  8. Minimal Residual Disease (MRD) Negativity Rate - Primary Analysis

    The MRD negativity rate is defined as the percentage of participants who had MRD negative status with less than one CLL cell per 10,000 leukocytes (\< 10-⁴) in peripheral blood and bone marrow. MRD was evaluated using next-generation sequencing. Per protocol, peripheral blood MRD assessments were to be collected from all participants at Week 24 and Week 48 and at the time the bone marrow assessment for confirmation of CR/CRi, and bone marrow (BM) MRD assessments were to be collected for participants undergoing a bone marrow procedure for confirmation of CR/CRi. Participants with no blood or BM MRD assessments were included in the calculation of MRD negativity rate as not having MRD negative status.

    Time frame: From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.

  9. Minimal Residual Disease (MRD) Negativity Rate - Final Analysis

    The MRD negativity rate is defined as the percentage of participants who had MRD negative status with less than one CLL cell per 10,000 leukocytes (\< 10-⁴) in peripheral blood and bone marrow. MRD was evaluated using next-generation sequencing. Per protocol, peripheral blood MRD assessments were to be collected from all participants at Week 24 and Week 48 and at the time the bone marrow assessment for confirmation of CR/CRi, and bone marrow (BM) MRD assessments were to be collected for participants undergoing a bone marrow procedure for confirmation of CR/CRi. Participants with no blood or BM MRD assessments were included in the calculation of MRD negativity rate as not having MRD negative status.

    Time frame: From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.

07

Results

Posted May 4, 2020

Participant flow

Participants were enrolled at 59 sites in 19 countries. The primary analysis of results occurred after all participants completed the Week 48 disease assessment, with a data cut-off date of 30 June 2019.

Participant flow — Overall Study
MilestoneVenetoclax
Started258
Completed124
Not completed134
Withdrew: Death70
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up3
Withdrew: Transitioned to long-term extension study m19-388 (nct03844048)49
Withdrew: Other10

Outcome measures

PrimaryComplete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis

Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 Modified International Workshop for Chronic Lymphocytic Leukemia National Cancer Institute-Working Group (IWCLL NCI-WG) criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes. CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Number · percentage of participants
Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis
percentage of participantsVenetoclax
Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Primary Analysis35.1 (28.3 to 42.3)
Statistical analysis
  • Venetoclax · Binomial test · p = <0.001
SecondaryComplete Remission Rate in Participants Previously Treated With BCRi Therapy - Primary Analysis

Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Number · percentage of participants
Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Primary Analysis
percentage of participantsVenetoclax
Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Primary Analysis25.4 (15.5 to 37.5)
SecondaryOverall Response Rate (ORR) - Primary Analysis

Overall response rate was defined as the percentage of participants with an overall best response of CR, CRi, nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 modified IWCLL NCI-WG criteria assessed by the investigator. CR and CRi are defined above. nPR is defined as for CR but bone marrow nodules could be identified histologically. For PR at least 2 of the following must be met: * 50% decrease in peripheral blood lymphocyte count from the Baseline value; * 50% reduction in lymphadenopathy; * 50% reduction in the size of the liver and/or spleen (if abnormal prior to therapy); In addition at least 1 of the following criteria must be met: * Neutrophils \> 1,500/μL or ≥ 50% improvement over Baseline; * Platelets \> 100,000/μL or ≥ 50% improvement over Baseline; * Hemoglobin \> 11.0 g/dL or ≥ 50% improvement over Baseline without transfusions or exogenous growth factors. PR must have been confirmed at least 7 weeks later.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) - Primary Analysis
percentage of participantsVenetoclax
Overall Response Rate (ORR) - Primary Analysis79.8 (74.4 to 84.6)
SecondaryDuration of Overall Response (DOR) - Primary Analysis

Duration of response was defined as the time from the date of first response (CR, CRi, nPR, or PR) to the earliest date that progressive disease (PD) was objectively documented (radiographic or clinical) or death. Duration of response was analyzed by Kaplan-Meier (K-M) methodology. If a participant was still responding the data were censored at the date of the last available disease assessment prior to the data cutoff date.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Median · months
Duration of Overall Response (DOR) - Primary Analysis
monthsVenetoclax
Duration of Overall Response (DOR) - Primary Analysis25.2 (23.0 to 25.2)
SecondaryTime to Progression (TTP) - Primary Analysis

Time to progression was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical). Participants who did not experience disease progression were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline disease assessments were censored at the first dose date plus 1 day. Time to progression was estimated using Kaplan-Meier methodology.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Median · months
Time to Progression (TTP) - Primary Analysis
monthsVenetoclax
Time to Progression (TTP) - Primary Analysis30.5 (29.6 to 30.5)
SecondaryProgression-Free Survival (PFS) - Primary Analysis

Progression-free survival (PFS) was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical) or death. Participants who did not experience disease progression or death were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline tumor assessment or clinical assessment for progression were censored at the date of first dose plus 1 day. Progression-free survival was analyzed by Kaplan-Meier methodology.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Median · months
Progression-Free Survival (PFS) - Primary Analysis
monthsVenetoclax
Progression-Free Survival (PFS) - Primary Analysis30.5 (28.6 to 30.5)
SecondaryOverall Survival (OS) - Primary Analysis

Overall survival (time to death) was defined as the time from the first dose date of venetoclax to the date of death. If a participant had not died the data were censored at the date when they were last known to be alive prior to the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Median · months
Overall Survival (OS) - Primary Analysis
monthsVenetoclax
Overall Survival (OS) - Primary AnalysisNA (NA to NA)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy - Leukemia Questionnaire (FACT-Leu)

The FACT-Leu is a 44-item, leukemia-specific questionnaire designed to assess health-related quality of life (HRQoL) and leukemia-specific symptoms using a core set of questions (Functional Assessment of Cancer Therapy-General; FACT-G), and a cancer site-specific leukemia subscale. Questions are scored on a scale from 0 (not at all) to 4 (very much). FACT-G consists of 27 general items divided into 4 primary HRQoL domains: Physical Well-being (PWB; 7 items; score range 0-28), Social/Family Well-being (SWB; 7 items; score range 0-28), Emotional Well-being (EWB; 6 items; score range 0-24), Functional Well-being (FWB; 7 items; score range 0-28). The leukemia subscale consists of 17 items (score range 0-68) that assess patient concerns relating to leukemia. Three summary scales were calculated: FACT-Trial Outcome Index composed of the PWB, FWB, and leukemia subscale (score range 0-124); FACT-G (score range 0-108) and the FACT-Leu Total (range 0-176). Higher scores reflect better HRQoL.

Time frame:
Baseline and Weeks 48 and 108
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Cancer Therapy - Leukemia Questionnaire (FACT-Leu)
score on a scaleVenetoclax
Physical well-being - Week 481.2 ± 4.07
Physical well-being - Week 1080.9 ± 4.20
Social/family well-being - Week 480.2 ± 5.14
Social/family well-being - Week 108-0.4 ± 4.86
Emotional well-being - Week 482.1 ± 3.52
Emotional well-being - Week 1081.7 ± 3.94
Functional well-being - Week 481.8 ± 5.63
Functional well-being - Week 1081.4 ± 5.67
Leukemia subscale - Week 486.8 ± 7.99
Leukemia subscale - Week 1086.0 ± 9.08
FACT-G total score - Week 485.5 ± 12.34
FACT-G total score - Week 1083.6 ± 13.56
FACT-leukemia trial outcome index - Week 489.8 ± 14.23
FACT-leukemia trial outcome index - Week 1088.2 ± 15.61
FACT-leukemia total score - Week 4812.3 ± 18.18
FACT-leukemia total score - Week 1089.5 ± 20.62
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue)

The FACIT-Fatigue questionnaire measures fatigue and its effect on functioning and daily activities. The FACIT-Fatigue includes 13 items answered on a 5-point rating scale based on a 7-day recall period. Scores range from 0 to 52, with lower scores reflecting greater fatigue.

Time frame:
Baseline and Weeks 48 and 108
Reported as:
Mean · score on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-Fatigue)
score on a scaleVenetoclax
Week 484.9 ± 9.43
Week 1083.3 ± 9.96
SecondaryChange From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Health Index Score

The EQ-5D-5L is a generic measure of health status consisting of two parts: a descriptive system consisting of 5 items and a visual analog scale (VAS). The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. The participant is asked to rate each dimension on 5 levels of severity (1: no problems, 2: slight problems, 3: moderate problems, 4: severe problems, 5: extreme problems). The scores for the 5 dimensions are used to compute a single health utility index score representing the general health status of the individual. The health index score ranges from zero (defined as a health state equivalent to being dead) to 1 (full health).

Time frame:
Baseline and Weeks 48 and 108
Reported as:
Mean · score on a scale
Change From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Health Index Score
score on a scaleVenetoclax
Week 480.0 ± 0.14
Week 1080.0 ± 0.15
SecondaryChange From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Visual Analog Scale Score

The EQ-5D-5L is a generic measure of health status consisting of two parts, a descriptive system consisting of 5 items and a visual analog scale (VAS). The VAS assesses the participant's self-rated overall health on a scale from 0 (worst health imaginable) to 100 (best health imaginable).

Time frame:
Baseline and Weeks 48 and 108
Reported as:
Mean · score on a scale
Change From Baseline in EuroQoL 5 Dimension 5 Level Questionnaire (EQ-5D-5L) Visual Analog Scale Score
score on a scaleVenetoclax
Week 488.5 ± 14.43
Week 1087.1 ± 14.61
Other pre-specifiedComplete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Final Analysis

Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes. CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Number · percentage of participants
Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Final Analysis
percentage of participantsVenetoclax
Complete Remission Rate in Participants Not Previously Treated With BCRi Therapy - Final Analysis34.6 (27.8 to 41.8)
Statistical analysis
  • Venetoclax · Binomial test · p = <0.001
Other pre-specifiedComplete Remission Rate in Participants Previously Treated With BCRi Therapy - Final Analysis

Complete remission rate is defined as the percentage of participants achieving a best response of complete remission (CR) or complete remission with incomplete marrow recovery (CRi) assessed by the investigator based on 2008 modified IWCLL NCI-WG criteria. CR required all of the following: * Peripheral blood lymphocytes \< 4000/μL * Absence of lymphadenopathy by physical examination and computed tomography scan * No hepatomegaly or splenomegaly by physical examination * Absence of disease or constitutional symptoms (unexplained fevers \> 38°C, drenching night sweats, \> 10% weight loss in last 6 months) * Blood counts above the following: * Neutrophils \> 1500/μL * Platelets \> 100,000/μL * Hemoglobin \> 110 g/L * Bone marrow at least normocellular for age, \< 30% lymphocytes CRi was defined as for CR but with persistent cytopenia apparently unrelated to CLL but related to drug toxicity.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Number · percentage of participants
Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Final Analysis
percentage of participantsVenetoclax
Complete Remission Rate in Participants Previously Treated With BCRi Therapy - Final Analysis26.9 (16.8 to 39.1)
Other pre-specifiedOverall Response Rate (ORR) - Final Analysis

Overall response rate was defined as the percentage of participants with an overall best response of CR, CRi, nodular partial remission (nPR), or confirmed partial remission (PR) based on the 2008 modified IWCLL NCI-WG criteria assessed by the investigator. CR and CRi are defined above. nPR is defined as for CR but bone marrow nodules could be identified histologically. For PR at least 2 of the following must be met: * 50% decrease in peripheral blood lymphocyte count from the Baseline value; * 50% reduction in lymphadenopathy; * 50% reduction in the size of the liver and/or spleen (if abnormal prior to therapy); In addition at least 1 of the following criteria must be met: * Neutrophils \> 1,500/μL or ≥ 50% improvement over Baseline; * Platelets \> 100,000/μL or ≥ 50% improvement over Baseline; * Hemoglobin \> 11.0 g/dL or ≥ 50% improvement over Baseline without transfusions or exogenous growth factors. PR must have been confirmed at least 7 weeks later.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) - Final Analysis
percentage of participantsVenetoclax
Overall Response Rate (ORR) - Final Analysis79.8 (74.4 to 84.6)
Other pre-specifiedDuration of Overall Response (DOR) - Final Analysis

Duration of response was defined as the time from the date of first response (CR, CRi, nPR, or PR) to the earliest date that progressive disease (PD) was objectively documented (radiographic or clinical) or death. Duration of response was analyzed by Kaplan-Meier (K-M) methodology. If a participant was still responding the data were censored at the date of the last available disease assessment prior to the data cutoff date.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Median · months
Duration of Overall Response (DOR) - Final Analysis
monthsVenetoclax
Duration of Overall Response (DOR) - Final Analysis25.1 (19.4 to 28.6)
Other pre-specifiedTime to Progression (TTP) - Final Analysis

Time to progression was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical). Participants who did not experience disease progression were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline disease assessments were censored at the first dose date plus 1 day. Time to progression was estimated using Kaplan-Meier methodology.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Median · months
Time to Progression (TTP) - Final Analysis
monthsVenetoclax
Time to Progression (TTP) - Final Analysis28.3 (23.4 to 32.6)
Other pre-specifiedProgression-Free Survival (PFS) - Final Analysis

Progression-free survival (PFS) was defined as the time from the date of first dose of venetoclax to the date of earliest PD (radiographic or clinical) or death. Participants who did not experience disease progression or death were censored at the date of the last available disease assessment prior to the data cutoff date; participants with no post-baseline tumor assessment or clinical assessment for progression were censored at the date of first dose plus 1 day. Progression-free survival was analyzed by Kaplan-Meier methodology.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Median · months
Progression-Free Survival (PFS) - Final Analysis
monthsVenetoclax
Progression-Free Survival (PFS) - Final Analysis28.3 (22.2 to 30.5)
Other pre-specifiedOverall Survival (OS) - Final Analysis

Overall survival (time to death) was defined as the time from the first dose date of venetoclax to the date of death. If a participant had not died the data were censored at the date when they were last known to be alive prior to the cutoff date. Overall survival was analyzed using Kaplan-Meier methodology.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Median · months
Overall Survival (OS) - Final Analysis
monthsVenetoclax
Overall Survival (OS) - Final AnalysisNA (NA to NA)
Other pre-specifiedMinimal Residual Disease (MRD) Negativity Rate - Primary Analysis

The MRD negativity rate is defined as the percentage of participants who had MRD negative status with less than one CLL cell per 10,000 leukocytes (\< 10-⁴) in peripheral blood and bone marrow. MRD was evaluated using next-generation sequencing. Per protocol, peripheral blood MRD assessments were to be collected from all participants at Week 24 and Week 48 and at the time the bone marrow assessment for confirmation of CR/CRi, and bone marrow (BM) MRD assessments were to be collected for participants undergoing a bone marrow procedure for confirmation of CR/CRi. Participants with no blood or BM MRD assessments were included in the calculation of MRD negativity rate as not having MRD negative status.

Time frame:
From first dose of study drug until the last participant completed Week 48 assessments (data cut-off date 30 June 2019); overall median time on follow-up was 23.2 months.
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Negativity Rate - Primary Analysis
percentage of participantsVenetoclax
Peripheral blood39.9 (33.9 to 46.2)
Bone marrow9.7 (6.4 to 14.0)
Other pre-specifiedMinimal Residual Disease (MRD) Negativity Rate - Final Analysis

The MRD negativity rate is defined as the percentage of participants who had MRD negative status with less than one CLL cell per 10,000 leukocytes (\< 10-⁴) in peripheral blood and bone marrow. MRD was evaluated using next-generation sequencing. Per protocol, peripheral blood MRD assessments were to be collected from all participants at Week 24 and Week 48 and at the time the bone marrow assessment for confirmation of CR/CRi, and bone marrow (BM) MRD assessments were to be collected for participants undergoing a bone marrow procedure for confirmation of CR/CRi. Participants with no blood or BM MRD assessments were included in the calculation of MRD negativity rate as not having MRD negative status.

Time frame:
From first dose of study drug until the end of study; overall median time on follow-up was 49.5 months.
Reported as:
Number · percentage of participants
Minimal Residual Disease (MRD) Negativity Rate - Final Analysis
percentage of participantsVenetoclax
Peripheral blood40.3 (34.3 to 46.6)
Bone marrow10.5 (7.0 to 14.9)

Adverse events

Collected over All-cause mortality are reported up to the end of the study; median time on study was 210 weeks. Adverse events are reported from the first dose of venetoclax up to 30 days after the last dose of venetoclax; Median (minimum, maximum) duration of treatment was 108 (0.1, 254.6) weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Venetoclax70/258 (27.1%)136/258 (52.7%)246/258 (95.3%)
Most frequent serious events
Showing 10 of 170
Most frequent serious events
EventVenetoclax
PNEUMONIAInfections and infestations21/258
FEBRILE NEUTROPENIABlood and lymphatic system disorders15/258
PYREXIAGeneral disorders11/258
ANAEMIABlood and lymphatic system disorders5/258
DIARRHOEAGastrointestinal disorders5/258
DYSPNOEARespiratory, thoracic and mediastinal disorders5/258
NEUTROPENIABlood and lymphatic system disorders4/258
LOWER RESPIRATORY TRACT INFECTIONInfections and infestations4/258
BLOOD LACTATE DEHYDROGENASE INCREASEDInvestigations4/258
HYPERKALAEMIAMetabolism and nutrition disorders4/258
Most frequent other events
Showing 10 of 45
Most frequent other events
EventVenetoclax
NEUTROPENIABlood and lymphatic system disorders108/258
DIARRHOEAGastrointestinal disorders95/258
NAUSEAGastrointestinal disorders69/258
ANAEMIABlood and lymphatic system disorders57/258
THROMBOCYTOPENIABlood and lymphatic system disorders53/258
COUGHRespiratory, thoracic and mediastinal disorders52/258
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations47/258
FATIGUEGeneral disorders45/258
PYREXIAGeneral disorders43/258
NASOPHARYNGITISInfections and infestations39/258

Baseline characteristics

Age, Continuous
Age, Continuous(years)Venetoclax
Mean67.7 ± 9.04
Age, Customized
Age, Customized(Participants)Venetoclax
< 65 years94
>= 65 years164
Sex: Female, Male
Sex: Female, Male(Participants)Venetoclax
Female78
Male180
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Venetoclax
Hispanic or Latino9
Not Hispanic or Latino248
Unknown or Not Reported1
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Venetoclax
White252
Black or African American3
Asian2
Missing1
Geographic Region
Geographic Region(Participants)Venetoclax
Europe161
North America28
Rest of the World69
Prior Treatment With B-cell Receptor Inhibitor (BCRi)
Prior Treatment With B-cell Receptor Inhibitor (BCRi)(Participants)Venetoclax
BCRi-naive191
BCRi-exposed67
08

Study locations

67 sites
  • Norton Cancer Institute /ID# 149788
    Louisville, Kentucky 40202-3700, United States
  • St. Agnes Cancer Center /ID# 149782
    Baltimore, Maryland 21229, United States
  • Hackensack Univ Med Ctr /ID# 151574
    Hackensack, New Jersey 07601, United States
  • Utah Cancer Specialists /ID# 151604
    Salt Lake City, Utah 84106, United States
  • Cancer Care Northwest /ID# 151605
    Spokane, Washington 99202, United States
  • West Virginia Univ School Med /ID# 151602
    Morgantown, West Virginia 26506, United States
  • LKH-Univ. Klinikum Graz /ID# 147547
    Graz, 8036, Austria
  • LKH Salzburg and Paracelsus /ID# 147549
    Salzburg, 5020, Austria
  • Hanusch Krankenhaus der WGKK /ID# 147548
    Wien, 1140, Austria
  • Cliniques Universitaires Saint Luc /ID# 147388
    Woluwe-Saint-Lambert, Bruxelles-Capitale 1200, Belgium
  • UZ Leuven /ID# 147387
    Leuven, 3000, Belgium
  • BC Cancer Agency /ID# 153091
    Vancouver, British Columbia V5Z 1L3, Canada
  • Qe Ii Hsc /Id# 147460
    Halifax, Nova Scotia B3H 1V7, Canada
  • Juravinski Cancer Clinic /ID# 149152
    Hamilton, Ontario L8V 1C3, Canada
  • Sunnybrook Health Sciences Ctr /ID# 147462
    Toronto, Ontario M4N 3M5, Canada
  • CHU de Quebec-Universite Laval /ID# 150299
    Quebec City, Quebec G1R 2J6, Canada
  • Herlev Hospital /ID# 150183
    Herlev, Hovedstaden 2730, Denmark
  • Aarhus University Hospital /ID# 147409
    Aarhus N, Midtjylland 8200, Denmark
  • Turku University Hospital /ID# 147551
    Turku, 20520, Finland
  • CHU Dupuytren /ID# 147552
    Limoges CEDEX 1, Franche-Comte 87042, France
  • CHU de la miletrie /ID# 147484
    Poitiers, Poitou-Charentes 86021, France
  • Institut Bergonie /ID# 147482
    Bordeaux, 33076, France
  • CHRU de Brest - Hopital Morvan /ID# 147485
    Brest, 29200, France
  • clinique Sainte Anne /ID# 147556
    Strasbourg, 67085, France
  • Onkologische Schwerpunktpraxis /ID# 147516
    Berlin, 10707, Germany
  • Cent fuer Haematologie und Onk /ID# 147511
    Frankfurt, 60389, Germany
  • OncoResearch Lerchenfeld GmbH /ID# 164044
    Hamburg, 22081, Germany
  • Mannheimer Onkologiepraxis /ID# 147512
    Mannheim, 68161, Germany
  • Staedt. Klinikum Schwabing /ID# 147510
    Munich, 80804, Germany
  • General Hospital of Athens Laiko /ID# 147517
    Athens, Attiki 115 27, Greece
  • G. Papanikolaou Hospital /ID# 147518
    Thessaloniki, 57010, Greece
  • St. James's Hospital /ID# 147519
    Dublin 8, Dublin D08 E9P6, Ireland
  • Beaumont Hospital /ID# 147522
    Dublin, D09 XR63, Ireland
  • Tel Aviv Sourasky Medical Ctr /ID# 151624
    Tel Aviv-Yafo, Tel-Aviv 6423906, Israel
  • Galilee Medical Center /ID# 159971
    Nahariya, 22100, Israel
  • Sheba Medical Center /ID# 147509
    Ramat Gan, 5262100, Israel
  • A.O.U. Policlinico S.Orsola-Malpighi /ID# 147505
    Bologna, Emilia-Romagna 40138, Italy
  • AP Romano Umberto I /ID# 147500
    Rome, Lazio 00161, Italy
  • ASST Grande Ospedale Metropolitano Niguarda /ID# 147503
    Milano, Lombardia 20162, Italy
  • Ospedale San Raffaele IRCCS /ID# 147504
    Milan, 20132, Italy
  • AO Maggiore della Carita /ID# 147499
    Novara, 28100, Italy
  • Academisch Medisch Centrum /ID# 147494
    Amsterdam, Noord-Holland 1105 AZ, Netherlands
  • Albert Schweitzer Ziekenhuis /ID# 147495
    Dordrecht, Zuid-Holland 3318 AT, Netherlands
  • Haukeland University Hospital /ID# 147382
    Bergen, Hordaland 5021, Norway
  • Rikshospitalet OUS HF /ID# 201812
    Oslo, 0450, Norway
  • IPO Lisboa FG, EPE /ID# 147385
    Lisboa, 1099-023, Portugal
  • IPO Porto FG, EPE /ID# 147389
    Porto, 4200-072, Portugal
  • Puerto Rico Hematology Oncolog /ID# 150003
    San Juan, 00959, Puerto Rico
  • Hospital Santa Creu i Sant Pau /ID# 151230
    Barcelona, 08026, Spain
  • Fundacion Jimenez Diaz /ID# 151231
    Madrid, 28040, Spain
  • Hosp Univ Puerta de Hierro /ID# 147391
    Majadahonda, 28222, Spain
  • Hospital Clinico Univ de Salamanca /ID# 147392
    Salamanca, 37007, Spain
  • Hosp Clin Univ de Valencia /ID# 147396
    València, 46010, Spain
  • Skanes Universitetssjukhus Lund /ID# 147439
    Lund, Skane Lan 222 41, Sweden
  • Akademiska Sjukhuset /ID# 150184
    Uppsala, Uppsala Lan 751 85, Sweden
  • Hopitaux Universitaires de Geneve /ID# 147930
    Genève, Geneve 1205, Switzerland
  • University Hospital Zurich /ID# 157910
    Zurich, Zuerich 8006, Switzerland
  • Ospedale Regional Bellinzona e /ID# 151232
    Bellinzona, 6501, Switzerland
  • Ankara Univ Medical Faculty /ID# 147443
    Ankara, 6100, Turkey
  • Istanbul University Istanbul Medical Faculty /ID# 156040
    Istanbul, 34093, Turkey
  • Vehbi Koc vakfi Amerikan Hasta /ID# 147325
    Istanbul, 34365, Turkey
  • Dokuz Eylul University /ID# 147442
    Izmir, 35340, Turkey
  • Ondokuz mayis University Facul /ID# 147326
    Samsun, 55139, Turkey
  • Blackpool Teaching Hosp NHS /ID# 149581
    Blackpool, FY3 8NR, United Kingdom
  • Univ Hosp Bristol NHS Foundati /ID# 147647
    Bristol, BS2 8EG, United Kingdom
  • Southampton General Hospital /ID# 147646
    Southampton, SO16 6YD, United Kingdom
  • The Royal Wolverhampton NHS Tr /ID# 147945
    Wolverhampton, WV10 0QP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols and clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing, please refer to the link below.

Access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous, independent scientific research, and will be provided following review and approval of a research proposal and Statistical Analysis Plan (SAP) and execution of a Data Sharing Agreement (DSA). For more information on the process, or to submit a request, visit the following link.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2016 to primary completion in Apr 2019, 33 months.

Results were first posted in May 2020, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 33 months is below that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2016
First posted
Apr 29, 2016
StartActual
Jun 22, 2016
Primary completionActual
Apr 10, 2019
CompletionActual
Mar 11, 2022
Results first posted
May 4, 2020
Last update
Apr 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02756611
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Apr 29, 2016
Start date
Jun 22, 2016
Primary completion
Apr 10, 2019
Completion
Mar 11, 2022
Results posted
May 4, 2020
Last update
Apr 10, 2023

Study contacts

AbbVie Inc.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion